biotech / news / / Seeking Alpha
Novo Nordisk (NVO) announced on Friday that an expert panel of the European Medicines Agency, the EU drug regulator, endorsed a single-dose pen.
Novo Nordisk received EMA panel endorsement for a 7.2 mg single-dose pen of Wegovy.
KEY POINTS
- This is the first time a 7.2 mg version of Wegovy is being recommended in the EU.
- The EMA's Committee issued a positive opinion specifically for the single-dose pen format.
- This regulatory endorsement could expand treatment options and ease of use for obesity patients in Europe.
COMPANIES
Summarized by Newsio from Seeking Alpha. How we summarize →